Sanofi $SNY Shares Purchased by Ethic Inc.

Key Points

• Ethic Inc. increased its holdings in Sanofi by 27.2% in the first quarter, bringing its total to 133,772 shares valued at approximately $7.27 million.
• Several hedge funds also significantly increased their positions in Sanofi, with Mirae Asset Global Investments increasing by 124% and Axxcess Wealth Management by 130.5% during the same period.
• Wall Street analysts have upgraded their ratings for Sanofi, with a consensus rating of "Buy" and a price target averaging $62.00.

Ethic Inc. increased its position in Sanofi (NASDAQ:SNY - Free Report) by 27.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 133,772 shares of the company's stock after acquiring an additional 28,645 shares during the period. Ethic Inc.'s holdings in Sanofi were worth $7,269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of SNY. Bank of America Corp DE grew its holdings in Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock valued at $579,587,000 after buying an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock valued at $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Federated Hermes Inc. grew its holdings in Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock valued at $218,933,000 after buying an additional 1,456,269 shares during the last quarter. Nuveen Asset Management LLC grew its holdings in Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock valued at $177,304,000 after buying an additional 34,660 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in Sanofi by 6.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock valued at $181,764,000 after buying an additional 211,641 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res raised Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Finally, Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $62.00.

Sanofi Trading Up 0.1%

Shares of SNY traded up $0.07 during trading hours on Monday, hitting $49.84. The stock had a trading volume of 3,945,271 shares, compared to its average volume of 2,659,869. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The firm has a market cap of $122.38 billion, a P/E ratio of 11.98, a P/E/G ratio of 1.19 and a beta of 0.48. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company's fifty day simple moving average is $48.57 and its 200 day simple moving average is $51.78.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same quarter in the prior year, the company posted $1.73 earnings per share. The firm's revenue for the quarter was down 7.0% on a year-over-year basis. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.